C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and β-glucan

Journal of Immunology

Volumn 174, Issue 11, 2005, Pages 7050-7056

  Allendorf, Daniel J ^a   Yan, Jun ^a,b   Ross, Gordon D ^a   Hansen, Richard D ^a   Baran, Jarek T ^a,c   Subbarao, Krishnaprasad ^a,d   Wang, Li ^a   Haribabu, Bodduluri ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d Aurigene Discovery Technologies Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; CD11B ANTIGEN; CD18 ANTIGEN; COMPLEMENT COMPONENT C5A; GANGLIOSIDE GD2; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GRANULOCYTE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MACROPHAGE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OPSONIZATION; PERITONEAL CAVITY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR MODEL; TUMOR REGRESSION;

EID: 18944394199     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.11.7050     Document Type: Article

References (50)

1. Cheung, N. K., S. Modak, A. Vickers, and B. Knuckles. 2002. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. 51: 557-564.
2. Hong, F., R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross. 2003. β-Glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63: 9023-9031.
3. Hong, F., J. Yan, J. T. Baran, D. J. Allendorf, R. D. Hansen, G. R. Ostroff, P. X. Xing, N. K. Cheung, and G. D. Ross. 2004. Mechanism by which orally administered β-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 173: 797-806.
4. Wang, S. C., L. Zhang, G. N. Hortobagyi, and M. C. Hung. 2001. Targeting HER2: recent developments and future directions for breast cancer patients. Semin. Oncol 28: 21-29.
5. Gelderman, K. A., S. Tomlinson, G. D. Ross, and A. Gorter. 2004. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25: 158-164.
6. Niehans, G. A., D. L. Cherwitz, N. A. Staley, D. J. Knapp, and A. P. Dalmasso. 1996. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149: 129-142.
7. Yu, J., T. Caragine, S. Chen, B. P. Morgan, A. B. Frey, and S. Tomlinson. 1999. Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59. Clin. Exp. Immunol. 115: 13-18.
8. Li, L., I. Spendlove, J. Morgan, and L. G. Durrant. 2001. CD55 is over-expressed in the tumour environment. Br. J. Cancer 84: 80-86.
9. Vetvicka, V., B. P. Thornton, and G. D. Ross. 1996. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98: 50-61.
10. Vetvicka, V., B. P. Thornton, T. J. Wieman, and G. D. Ross. 1997. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J. Immunol. 159: 599-605.
11. Cain, J. A., S. L. Newman, and G. D. Ross. 1987. Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement 4: 75-86.
12. Ross, G. D., J. A. Cain, B. L. Myones, S. L. Newman, and P. J. Lachmann. 1987. Specificity of membrane complement receptor type three (CR3) for β-glucans. Complement 4: 61-74.
13. Thornton, B. P., V. Vetvicka, M. Pitman, R. C. Goldman, and G. D. Ross. 1996. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156: 1235-1246.
14. Xia, Y., and G. D. Ross. 1999. Generation of recombinant fragments of CD11b expressing the functional β-glucan-binding lectin site of CR3 (CD11b/CD18). J. Immunol. 162: 7285-7293.
15. Xia, Y., V. Vetvicka, J. Yan, M. Hanikyrova, T. Mayadas, and G. D. Ross. 1999. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 162: 2281-2290.
16. Yan, J., V. Vetvicka, Y. Xia, M. Hanikyrova, T. N. Mayadas, and G. D. Ross. 2000. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble β-glucan. Immunopharmacology 46: 39-54.
17. Cheung, N. K., and S. Modak. 2002. Oral (1→3),(1→4)-β-D- glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. 8: 1217-1223.
18. Zwirner, J., O. Gotze, G. Begemann, A. Kapp, K. Kirchhoff, and T. Werfel. 1999. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 97: 166-172.
19. Ehrengruber, M. U., T. Geiser, and D. A. Deranleau. 1994. Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett. 346: 181-184.
20. 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood 85: 2900-2909.
21. Petering, H., J. Kohl, A. Weyergraf, Y. Dulkys, D. Kimmig, R. Smolarski, A. Kapp, and J. Elsner. 2000. Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a. J. Immunol. 164: 3783-3789.
22. Robertson, M. J., and J. Ritz. 1990. Biology and clinical relevance of human natural killer cells. Blood 76: 2421-2438.
23. Papamichail, M., S. A. Perez, A. D. Gritzapis, and C. N. Baxevanis. 2004. Natural killer lymphocytes: biology, development, and function. Cancer Immunol. Immunother. 53: 176-186.
24. Ember, J. A., and T. E. Hugli. 1997. Complement factors and their receptors. Immunopharmacology 38: 3-15.
25. Sengelov, H. 1995. Complement receptors in neutrophils. Crit. Rev. Immunol. 15: 107-131.
26. Haviland, D. L., R. L. McCoy, W. T. Whitehead, H. Akama, E. P. Molmenti, A. Brown, J. C. Haviland, W. C. Parks, D. H. Perlmutter, and R. A. Wetsel. 1995. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol. 154: 1861-1869.
27. Riedemann, N. C., R. F. Guo, V. J. Sarma, I. J. Laudes, M. Huber-Lang, R. L. Warner, E. A. Albrecht, C. L. Speyer, and P. A. Ward. 2002. Expression and function of the C5a receptor in rat alveolar epithelial cells. J. Immunol. 168: 1919-1925.
28. Laudes, I. J., J. C. Chu, M. Huber-Lang, R. F. Guo, N. C. Riedemann, J. V. Sarma, F. Mahdi, H. S. Murphy, C. Speyer, K. T. Lu, et al. 2002. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 169: 5962-5970.
29. Haribabu, B., R. M. Richardson, M. W. Verghese, A. J. Barr, D. V. Zhelev, and R. Snyderman. 2000. Function and regulation of chemoattractant receptors. Immunol. Res. 22: 271-279.
30. 4 receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J. Exp. Med. 192: 433-438.
31. Ford-Hutchinson, A. W., M. A. Bray, M. V. Doig, M. E. Shipley, and M. J. Smith. 1980. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286: 264-265.
32. Samuelsson, B., S. E. Dahlen, J. A. Lindgren, C. A. Rouzer, and C. N. Serhan. 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237: 1171-1176.
33. Subbarao, K., V. R. Jala, S. Mathis, J. Suttles, W. Zacharias, J. Ahamed, H. Ali, M. T. Tseng, and B. Haribabu. 2004. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol. 24: 369-375.
34. Yokomizo, T., T. Izumi, K. Chang, Y. Takuwa, and T. Shimizu. 1997. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387: 620-624.
35. Raychaudhuri, S., Y. Saeki, H. Fuji, and H. Kohler. 1986. Tumor-specific idiotype vaccines, I. Generation and characterization of internal image tumor antigen. J. Immunol. 137: 1743-1749.
36. Hank, J. A., R. R. Robinson, J. Surfus, B. M. Mueller, R. A. Reisfeld, N. K. Cheung, and P. M. Sondel. 1990. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res. 50: 5234-5239.
37. Hestdal, K., F. W. Ruscetti, J. N. Ihle, S. E. Jacobsen, C. M. Dubois, W. C. Kopp, D. L. Longo, and J. R. Keller. 1991. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 147: 22-28.
38. Yan, J., V. Vetvicka, Y. Xia, A. Coxon, M. C. Carroll, T. N. Mayadas, and G. D. Ross. 1999. β-Glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. 163: 3045-3052.
39. Woodruff, T. M., A. J. Strachan, S. D. Sanderson, P. N. Monk, A. K. Wong, D. P. Fairlie, and S. M. Taylor. 2001. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 25: 171-177.
40. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegard, J. Kohl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877.
41. Kildsgaard, J., T. J. Hollmann, K. W. Matthews, K. Bian, F. Murad, and R. A. Wetsel. 2000. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165: 5406-5409.
42. Wipke, B. T., and P. M. Allen. 2001. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J. Immunol. 167: 1601-1608.
43. Binder, R., A. Kress, G. Kan, K. Hermann, and M. Kirschfink. 1999. Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): impact on C5a-mediated chemotaxis, degranulation and respiratory burst. Mol. Immunol. 36: 885-892.
44. Rao, T. S., J. L. Currie, A. F. Shaffer, and P. C. Isakson. 1994. In vivo characterization of zymosan-induced mouse peritoneal inflammation. J. Pharmacol. Exp. Ther. 269: 917-925.
45. Okinaga, S., D. Slattery, A. Humbles, Z. Zsengeller, O. Morteau, M. B. Kinrade, R. M. Brodbeck, J. E. Krause, H. R. Choe, N. P. Gerard, et al. 2003. C5L2, a nonsignaling C5A binding protein. Biochemistry 42: 9406-9415.
46. 4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192: 421-432.
47. Kaufman, H. L., and M. L. Disis. 2004. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J. Clin. Invest. 113: 664-667.
48. Maeda, H., and T. Akaike. 1998. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry 63: 854-865.
49. Enzler, T., S. Gillessen, J. P. Manis, D. Ferguson, J. Fleming, F. W. Alt, M. Mihm, and G. Dranoff. 2003. Deficiencies of GM-CSF and interferon γ link inflammation and cancer. J. Exp. Med. 197: 1213-1219.
50. Kuper, H., H. O. Adami, and D. Trichopoulos. 2000. Infections as a major preventable cause of human cancer. J. Intern. Med. 248: 171-183.